Skip to main content

Table 1 Mean (SD) [range] administered activity, length of stay in hospital, percentage 177Lu and activity retention at discharge for outpatient and inpatient administrations

From: Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours

  Number of administrations Number of patients Administered activity (MBq) Time T0TD (h) 177Lu retention (%) Retained activity (MBq)
Inpatients 32 16 7079 (419)
[5925–7890]
18.1 (1.5)
[16.2–21.2]
36 (15)
[15–62]
2537 (1079)
[1087–4482]
177Lu-DOTATATE Mallinckrodt
Inpatients 24 18 7545 (204)
[7076–7913]
18.2 (1.1)
[16.7–21.0]
24 (7)
[13–37]
1806 (494)
[984–2740]
 Lutathera® AAA
Outpatients 20 15 7608 (242)
[7259–8038]
5.2 (0.7)
[3.6–6.3]
38 (8)
[28–58]
2897 (663)
[2103–4670]
 Lutathera® AAA